Napamezole

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GK4C2D295B, chemically known as 2-((3,4-dihydro-2-naphthyl)methyl)-2-imidazoline but generally known as napamezole, which bears US NIH Compound Identifier 124655. European Medicines Agency schedules Napamezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09153MIG. The term NAPAMEZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). NAPAMEZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule napamezole under HS 29332990 and SITC 51573. As of Q4 2014, NAPAMEZOLE remains the US FDA Preferred Term for this commodity. Napamezole bears US NLM identifiers UMLS ID C0083703 and NCI Concept Code C83985. SMILES: N1CC(=NC1)CC1=CC2C(CC1)CCCC2.